NGVT

Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?

Ingevity is transforming into a focused, high-margin regulatory compounder, emphasizing Performance Materials and Pavement Technologies after divesting volatile, lower-quality segments. Q2 '26 results highlight margin inflection: adjusted EBITDA rose 14% to $115M, margin expanded to 36.6%, and EPS increased to $1.74, demonstrating strong operating leverage. Hybrid vehicle adoption and infrastructure spending underpin resilient demand for NGVT's emissions-control and pavement solutions, while PFAS filtration offers incremental EBITDA growth optionality.

NGVT's raised 2026 outlook, portfolio transformation and new growth platforms support its momentum and higher-return investment focus.

Ingevity's Q2 earnings beat estimates as pricing, mix and higher volumes lifted margins, prompting higher 2026 earnings and EBITDA guidance.

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity raises full year Adjusted EBITDA outlook following a solid start to the year.

Ingevity's Evotherm P35 earns German approval after rigorous testing, clearing it for use in warm-mix asphalt for federal projects.

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity announced Evotherm® P35 warm-mix additive has received approval from Germany's Federal Highway Research Institute, known as BASt.

NGVT shares are up 24.8% YTD, beating the industry, as portfolio optimization, hybrid demand and pricing actions drive earnings and boost outlook.

Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock?

Ingevity NYSE: NGVT reported higher first-quarter 2026 sales and reaffirmed its full-year outlook as management highlighted progress on portfolio simplification, strong margins in its Performance Materials business and continued share repurchases.